公开(公告)号：US20100160406A1

公开(公告)日：2010-06-24

申请号：US11909727

申请日：2006-03-28

申请人： Philip Arthur Hipskind ,  Takako Takakuwa ,  Cynthia Darshini Jesudason ,  Robert Alan Gadski ,  William Joseph Hornback ,  Richard Todd Pickard ,  Lisa Selsman Beavers

发明人： Philip Arthur Hipskind ,  Takako Takakuwa ,  Cynthia Darshini Jesudason ,  Robert Alan Gadski ,  William Joseph Hornback ,  Richard Todd Pickard ,  Lisa Selsman Beavers

IPC分类号： A61K31/4025 ,  C07D403/06 ,  A61P31/04

CPC分类号： C07D207/09 ,  C07D401/06

摘要： The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

摘要翻译： 本发明公开了具有组胺H3受体拮抗剂或反向激动剂活性的式（I）的新化合物或其药学上可接受的盐，以及制备这些化合物的方法和中间体。 在另一个实施方案中，本发明公开了包含式（I）化合物的药物组合物以及使用这些组合物治疗肥胖，认知缺陷，发作性睡病和其他组胺H3受体相关疾病的方法。